01 Industry overview
The molecular diagnostics industry at a glance
The global molecular diagnostics market is estimated at $20.1 billion in 2026, led by North America and supported by demand for infectious-disease, oncology and precision-medicine testing.
- $20.1B[3]
- Global market size, 2026
- 8.4%[3]
- Forecast CAGR, 2027–2035
- 44.7%[3]
- North America share, 2026
- $42B[6]
- Diagnostics M&A value, 2025
- Market size
- The global molecular diagnostics market was estimated at $20.1 billion in 2026 by Grand View Research. A separate estimate placed the market at $15.78 billion in 2025, illustrating the variation caused by differences in market scope and methodology.[3][7]
- Forecast & CAGR
- Grand View Research forecasts growth from $21.5 billion in 2027 to $40.9 billion in 2035, representing an 8.4% CAGR. Fortune Business Insights forecasts a more conservative 4.71% CAGR from 2026 to 2034, reaching $23.62 billion.[3][7]
- Market share & regions
- North America held 44.7% of global revenue in 2026, according to Grand View Research. Asia Pacific was identified as the fastest-growing regional market, with a projected 9.5% CAGR from 2027 to 2035.[3]
- Segmentation
- Consumables accounted for 70.0% of the market in 2026, while PCR held a 43.2% share by technology. Infectious-disease applications, blood and blood-derived specimens, and hospitals and clinics were the leading categories in their respective segments.[3]
- Key players & concentration
- Leading companies include Roche, Abbott, bioMérieux, QIAGEN, Danaher’s Cepheid business, Thermo Fisher Scientific and Hologic. Available market sources identify these companies as major participants but do not provide a consistent, independently verifiable concentration ratio for the industry.[7]
- Trends, drivers & challenges
- Growth is being supported by infectious-disease surveillance, oncology biomarker testing, rare-disease diagnosis, automation and biomarker-driven clinical decisions. Grand View Research also identifies centralized laboratory automation, expanded test menus and referral testing as important growth factors, while regulatory complexity and laboratory implementation costs remain constraints.[3][8]
- M&A
- Diagnostics M&A reached $42 billion in 2025, according to Deloitte, driven by spatial multi-omics, AI clinical bioinformatics and scalable molecular diagnostics. In December 2025, Natera completed its acquisition of Foresight Diagnostics for $275 million upfront plus up to $175 million in earnouts, adding ultrasensitive molecular residual-disease technology.[6][9]
- Regulation
- In the United States, FDA oversight of laboratory-developed tests remains a major regulatory issue. The FDA states that its May 6, 2024 LDT final rule was vacated by a federal district court on March 31, 2025, and that the agency issued a rule on September 19, 2025 reverting the regulation’s text; molecular diagnostic laboratories also remain subject to CMS CLIA requirements.[8][10]
- Latest news
- The FDA’s Molecular and Clinical Genetics Panel met on September 23, 2026 to discuss GRAIL’s PMA application for Galleri, an NGS-based blood test intended to detect cancer-specific methylation patterns. In 2026, FDA records also listed molecular and companion-diagnostic clearances involving Abbott and Roche.[8]
02 Ranking
Top 10 Companies in the Molecular Diagnostics Industry
The leading companies in the molecular diagnostics industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 21, 2026 · Next review December 21, 2026
Guardant Health stands out for oncology liquid biopsy molecular testing because it reported $683.6 million in 2025 oncology revenue from molecular testing, while Natera focuses on cell-free DNA and molecular genetic testing since it processed approximately 923,600 genetic and molecular tests in the fourth quarter of 2025.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in oncology liquid biopsy
Guardant Health
US
Ranked #1 · 9.3 · Oncology liquid biopsy
Why we picked it: It ties molecular testing revenue to oncology diagnostics scale, with $683.6 million in 2025 oncology revenue.
Leader in cell-free DNA testing
Natera
US
Ranked #2 · 9.2 · Cell-free DNA testing
Why we picked it: It stands out for molecular test throughput, processing about 923,600 genetic and molecular tests in Q4 2025.
Leader in PCR and sequencing systems
Roche
CH
Ranked #3 · 9.1 · PCR and sequencing systems
Why we picked it: Its breadth spans molecular diagnostics, PCR and sequencing, reflected in CHF 13.847 billion Diagnostics sales in 2025.
Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Guardant Health Oncology liquid biopsy · US | 9.3 | 8.2 | 9.9 | 9.9 | 9.5 | |
Company snapshot · Guardant Health · Data as of November 21, 2026 Guardant reported $683.6 million in 2025 oncology revenue from molecular testing.[11]
| |||||||
| 2 | Natera Cell-free DNA testing · US | 9.2 | 8.5 | 9.2 | 9.8 | 9.3 | |
Company snapshot · Natera · Data as of November 21, 2026 Natera processed approximately 923,600 genetic and molecular tests in the fourth quarter of 2025.[9]
| |||||||
| 3 | Roche PCR and sequencing systems · CH | 9.1 | 9.9 | 8.0 | 9.1 | 9.9 | |
Company snapshot · Roche · Data as of November 21, 2026 Roche reported CHF 13.847 billion in 2025 Diagnostics sales, including molecular laboratory systems.[12]
| |||||||
| 4 | QIAGEN Sample-to-insight assays · NL | 8.7 | 9.0 | 8.3 | 8.3 | 8.6 | |
Company snapshot · QIAGEN · Data as of November 21, 2026 QIAGEN serves clinical healthcare customers with sample-to-insight molecular diagnostic solutions.[13]
| |||||||
| 5 | bioMérieux Syndromic infectious testing · FR | 8.6 | 9.2 | 7.6 | 8.6 | 9.1 | |
Company snapshot · bioMérieux · Data as of November 21, 2026 bioMérieux reported €1.733 billion in 2025 molecular biology revenue, led by syndromic testing platforms.[14]
| |||||||
| 6 | Illumina Clinical sequencing and genomic diagnostics · US | 8.6 | 9.1 | 7.8 | 7.7 | 9.9 | |
Company snapshot · Illumina · Data as of November 21, 2026 Illumina is a global leader in sequencing and array-based solutions used in clinical genomic diagnostics.[15]
| |||||||
| 7 | Hologic Women's-health molecular diagnostics · US | 8.4 | 8.0 | 8.4 | 7.7 | 8.6 | |
Company snapshot · Hologic · Data as of November 21, 2026 Hologic's Panther and Panther Fusion systems support high-throughput molecular diagnostics.[16]
| |||||||
| 8 | Seegene Multiplex PCR molecular diagnostics · KR | 8.2 | 7.1 | 8.1 | 9.1 | 8.9 | |
Company snapshot · Seegene · Data as of November 21, 2026 Seegene develops and manufactures multiplex PCR molecular diagnostic reagents and instruments.[17]
| |||||||
| 9 | BD Molecular infectious-disease diagnostics · US | 8.1 | 8.6 | 7.7 | 7.9 | 7.5 | |
Company snapshot · BD · Data as of November 21, 2026 BD produces instruments and reagent systems for infectious-disease and cancer diagnostics.[18]
| |||||||
| 10 | QuidelOrtho Molecular and rapid infectious-disease diagnostics · US | 8.1 | 7.0 | 9.1 | 9.2 | 7.0 | |
Company snapshot · QuidelOrtho · Data as of November 21, 2026 QuidelOrtho is included among established molecular diagnostics equipment and reagent suppliers.[1]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 21, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 21). Top 10 companies in the molecular diagnostics industry. In Molecular Diagnostics Industry Statistics. Gitnux. https://gitnux.org/molecular-diagnostics-industry-statistics/#top-companies
Global molecular diagnostics market share by technology
Polymerase chain reaction (PCR) holds the largest share at 42.9%.
03 Trends & forecasts
Top 10 Molecular Diagnostics Industry Trends & Forecasts 2027
What is changing in the molecular diagnostics industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Market growth remains above eight percent
High confidenceGrand View Research estimates the global molecular diagnostics market at $20.1 billion in 2026 and forecasts growth from $21.5 billion in 2027 to $40.9 billion in 2035, equivalent to an 8.4% CAGR. The estimate reflects demand across infectious disease, oncology, liquid biopsy and biomarker testing.[3]
Forecast 2027: The market should reach approximately $21.5 billion in 2027, with growth remaining concentrated in oncology, infectious-disease testing and precision medicine. Confidence is high because the 2027 estimate is directly stated in the market forecast.
02Asia Pacific expands faster than mature markets
High confidenceAsia Pacific is identified as the fastest-growing regional molecular diagnostics market, with a projected 9.5% CAGR from 2027 to 2035. North America remains the largest region, accounting for 44.7% of global revenue in 2026.[3]
Forecast 2027: Asia Pacific should gain modest global share in 2027 as laboratory infrastructure, infectious-disease surveillance and access to molecular testing improve. North America will remain the largest revenue region, but its share is likely to edge down as Asia Pacific grows faster.
03Consumables continue to dominate revenue
High confidenceConsumables represented 70.0% of global molecular diagnostics revenue in 2026, according to Grand View Research. Recurring demand for reagents, assay kits and sample-preparation materials gives consumables a larger revenue base than instruments and software.[3]
Forecast 2027: Consumables should remain the largest product category in 2027, with installed instruments supporting recurring reagent and cartridge purchases. Growth should favor multiplex panels, oncology assays and decentralized cartridges rather than one-time instrument sales.
04PCR remains the leading technology
High confidencePCR accounted for 43.2% of the molecular diagnostics market by technology in 2026. Its installed base, established clinical workflows and broad assay availability continue to support adoption across infectious disease and oncology.[3]
Forecast 2027: PCR should retain the largest technology share in 2027, although sequencing and digital PCR will continue taking specialized applications in oncology, rare disease and residual-disease detection. Competitive pressure will focus on speed, multiplexing, automation and lower sample volumes.
05Respiratory testing stays surveillance-driven
High confidenceDuring the 2025–2026 respiratory season, U.S. laboratories reported 2,965,708 RSV PCR results, of which 118,014 were positive, and 3,125,738 SARS-CoV-2 PCR results, of which 136,081 were positive. CDC data show that nucleic-acid testing remains part of national respiratory-virus surveillance.[19][20]
Forecast 2027: In 2027, respiratory molecular testing should remain a recurring surveillance and outbreak-management market rather than return solely to emergency pandemic volumes. Multiplex respiratory panels and public-health laboratory networks are likely to capture most incremental demand.
06Oncology biomarkers broaden test utilization
High confidenceThe FDA’s authorized companion-diagnostics list includes molecular tests linked to therapies and biomarkers such as ERBB2/HER2, while Grand View Research identifies oncology biomarker testing and biomarker-linked treatment selection as major market drivers.[8][3]
Forecast 2027: Oncology should generate disproportionate molecular-diagnostics growth in 2027 as more therapies require biomarker confirmation. Demand will favor tests that combine multiple actionable variants, shorten turnaround time and support treatment selection from limited tissue or blood samples.
07Companion diagnostics become more integrated
High confidenceThe FDA maintains a growing list of authorized companion diagnostics whose use is tied to therapeutic-product labeling. The list includes molecular and hybrid testing approaches for cancer and infectious-disease indications, illustrating the integration of drug and diagnostic development.[8]
Forecast 2027: In 2027, pharmaceutical developers should increasingly seek co-development or formal companion-diagnostic partnerships before launch. This will shift competition toward regulatory evidence, clinical trial integration and access to testing networks, not only analytical performance.
08MRD testing attracts precision-oncology capital
High confidenceNatera completed its acquisition of Foresight Diagnostics in December 2025 for $275 million upfront plus up to $175 million in earnouts. Foresight’s molecular residual-disease technology reported a limit of detection of 0.3 parts per million and detection below 0.1 parts per million.[9]
Forecast 2027: Molecular residual-disease testing should expand in 2027 from clinical trials into treatment-monitoring and recurrence-risk workflows, particularly in hematologic malignancies and selected solid tumors. M&A and licensing will remain important routes for established diagnostic companies to acquire ultrasensitive detection technologies.
09Liquid biopsy and NGS move toward validation
Medium confidenceThe FDA’s September 2026 advisory-panel materials describe GRAIL’s Galleri as an NGS-based test intended to detect cancer-specific methylation patterns in cell-free DNA from peripheral blood. The panel reviewed performance measures including sensitivity, specificity, predictive values and cancer-stage results.[8]
Forecast 2027: In 2027, liquid-biopsy developers will focus more heavily on clinical utility, false-positive management, reimbursement and regulatory evidence than on analytical novelty alone. NGS-based blood testing should advance selectively, with adoption strongest where results change treatment or surveillance decisions.
10AMR testing gains policy support
High confidenceIn November 2026, the World Health Organization published an essential package covering rapid, culture-based, serological and molecular tests for bacterial and fungal infections and antimicrobial resistance. WHO states that reliable testing is needed to guide antimicrobial use, strengthen surveillance and improve outcomes.[21]
Forecast 2027: Antimicrobial-resistance testing should see stronger public-sector procurement and implementation activity in 2027, particularly for rapid molecular identification and resistance-marker detection. Commercial uptake will remain uneven because reimbursement, laboratory capacity and affordability constrain adoption in lower-resource settings.
04 Statistics
Market Intelligence
The market intelligence range for 2026 spans $19.34 billion in 2025 to $20.1 billion in 2026, with projected growth to USD 40.9 billion in 2035 at 8.4% CAGR.
Market size, volume and shipments in the molecular diagnostics industry
- USD 21.68 billion was the estimated 2026 global molecular diagnostics market, covering kits, instruments and software across laboratory and point-of-care testing; MarketsandMarkets defines the category by product, test type, sample, technology, application and end user.[1]
- USD 18.17 billion was the estimated 2022 global molecular diagnostics market, covering disease areas, technologies, products and services, end users and geographic markets.[2]
- USD 20.1 billion was the estimated 2026 global molecular diagnostics market, covering instruments, consumables, software and services across clinical applications and end users.[3]
- USD 19.34 billion was the estimated 2025 global molecular diagnostics market, covering PCR, sequencing, hybridization, microarrays, mass spectrometry and other technologies across applications and end users.[4]
Forecast growth and shipments in the molecular diagnostics industry
- 8.4% is the projected CAGR for the global molecular diagnostics market from 2027 to 2035, with value rising from USD 21.5 billion in 2027 to USD 40.9 billion in 2035.[3]
- 9.86% is the projected CAGR for the global molecular diagnostics market from 2026 to 2033, with value rising from USD 21.24 billion in 2026 to USD 41.02 billion in 2033.[4]
- 8.5% is the projected CAGR for the global molecular diagnostics market from 2026 to 2031, with value rising from USD 21.68 billion in 2026 to USD 32.56 billion in 2031.[1]
05 Statistics
Regulation & Risk
U.S. FDA product code QLT records show 755 adverse-event entries tied to false-positive results as of September 7, 2026, alongside eight Class II recalls.
Recalls and safety notices for molecular diagnostics
- 2 medical-device reports were recorded for 2025 for U.S. FDA product code QLT, covering multi-analyte nucleic-acid-based molecular diagnostic devices; the FDA TPLC page was updated September 7, 2026.[5]
- 755 adverse-event records identified false-positive results for U.S. FDA product code QLT molecular diagnostic devices in the FDA TPLC database as of September 7, 2026.[5]
- 8 recalls were listed as of September 7, 2026 for U.S. FDA product code QLT, covering multi-analyte nucleic-acid-based molecular diagnostic devices; all listed recalls were Class II.[5]
Key questions about the molecular diagnostics industry
What is the molecular diagnostics market size in 2026?
How fast does the molecular diagnostics market grow after 2026?
Which companies lead the molecular diagnostics industry?
Which technology has the largest share of molecular diagnostics in 2026?
How is the molecular diagnostics market structured by region and application drivers?
What regulatory and risk factors show up in the U.S. for molecular diagnostics?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Samuel Norberg. (2026, November 21). Molecular Diagnostics Industry Statistics. Gitnux. https://gitnux.org/molecular-diagnostics-industry-statistics
Samuel Norberg. "Molecular Diagnostics Industry Statistics." Gitnux, 21 Nov 2026, https://gitnux.org/molecular-diagnostics-industry-statistics.
Samuel Norberg. 2026. "Molecular Diagnostics Industry Statistics." Gitnux. https://gitnux.org/molecular-diagnostics-industry-statistics.
Sources & references
21 sources cited across this report
marketsandmarkets.com
theinsightpartners.com
grandviewresearch.com
kingsresearch.com
accessdata.fda.gov
deloitte.com
fortunebusinessinsights.com
fda.gov
natera.com
cms.gov
ebs.publicnow.com
assets.roche.com
corporate.qiagen.com
biomerieux.com
sec.gov
hologic.com
seegene.com
investors.bd.com
cdc.gov
data.cdc.gov
who.int
